1. Home
  2. AIRT vs IMMP Comparison

AIRT vs IMMP Comparison

Compare AIRT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air T Inc.

AIRT

Air T Inc.

HOLD

Current Price

$22.37

Market Cap

60.5M

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

N/A

Current Price

$0.37

Market Cap

58.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AIRT
IMMP
Founded
1980
1987
Country
United States
Australia
Employees
646
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.5M
58.2M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
AIRT
IMMP
Price
$22.37
$0.37
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$5.50
AVG Volume (30 Days)
2.3K
3.1M
Earning Date
02-13-2026
02-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$382.75
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.56
$0.38
52 Week High
$26.70
$3.53

Technical Indicators

Market Signals
Indicator
AIRT
IMMP
Relative Strength Index (RSI) 49.21 13.31
Support Level $20.81 N/A
Resistance Level $23.92 $1.90
Average True Range (ATR) 0.55 0.09
MACD 0.11 -0.19
Stochastic Oscillator 51.90 0.58

Price Performance

Historical Comparison
AIRT
IMMP

About AIRT Air T Inc.

Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: